FDA Accepts Bristol Myers Squibb's NDA for Iberdomide in Relapsed or Refractory Multiple Myeloma
Feb 17, 2026
The U.S. FDA has accepted Bristol Myers Squibb's New Drug Application for iberdomide combined with daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma, with a PDUFA date of August 17, 2026.